Aytu BioPharma, Inc. develops and commercializes prescription medicines focused on complex central nervous system diseases. Its recurring company updates center on EXXUA (gepirone) extended-release tablets, an FDA-approved selective serotonin 5HT1a receptor agonist for major depressive disorder in adults, along with its ADHD products and legacy pediatric portfolio.
News from Aytu also covers operational and financial results, commercial launch activity, retail and Aytu RxConnect patient-access distribution, investor presentations, and product-level clinical and safety information for EXXUA. The company is a Nasdaq-listed specialty pharmaceutical issuer with prescription products sold through commercial distribution channels.
Aytu BioPharma (NASDAQ:AYTU) announced that CFO Mark Oki and CCO Greg Pyszczymuka will participate in a fireside chat at the 34th Annual Roth Conference on March 15, 2022, at 2:00 p.m. PT in Dana Point, California. The conference runs from March 13-15. A live webcast will be accessible on the company’s website and archived for 90 days.
Aytu BioPharma specializes in developing therapeutics for rare pediatric disorders and offers prescription products for ADHD and allergy treatment, along with a pipeline drug, AR101, for vascular Ehlers-Danlos Syndrome.
Aytu BioPharma announced the closing of an underwritten offering, raising $7.6 million through the sale of 3,030,000 shares of common stock and associated warrants. Each share and pre-funded warrant was priced at $1.25, with warrants exercisable for 1.1 shares at $1.30. The proceeds will support growth initiatives, including the PREVEnt Trial for AR101, aimed at treating vascular Ehlers-Danlos Syndrome. There is no public market for the pre-funded and common warrants. Canaccord Genuity and Roth Capital Partners facilitated the offering.
Aytu BioPharma (NASDAQ:AYTU) announced an underwritten offering of 3,030,000 shares of common stock and related warrants to a healthcare-dedicated institutional investor, aiming for approximately $7.6 million in gross proceeds. Each share and pre-funded warrant are priced at $1.25, with associated common warrants exercisable for 1.1 shares at $1.30. The proceeds will support the company’s commercial business growth, advance development of pipeline assets like AR101 for treating vascular Ehlers-Danlos Syndrome, and cover working capital needs. Closing is expected by March 7, 2022.
Aytu BioPharma (NASDAQ:AYTU) announced that the European Commission has granted orphan designation for AR101 (enzastaurin), a PKCβ inhibitor, intended for treating Ehlers-Danlos Syndrome (EDS), particularly the severe subtype vascular EDS (VEDS). This follows a similar designation from the FDA. The company plans to start a clinical trial, PREVEnt, in mid-2022 to evaluate AR101's safety and efficacy in VEDS patients. Orphan designation provides benefits such as reduced regulatory fees and market exclusivity for 10 years.
Aytu BioPharma reported a 53% year-over-year increase in net revenue, reaching $23.1 million for Q2 2022. Prescription sales surged over 103% to $14.6 million, with ADHD products achieving all-time highs. Despite this, net loss widened to $11.5 million or $0.44 per share. Notable advancements include FDA clearance for AR101, designated for treating Vascular Ehlers-Danlos Syndrome, and the initiation of a clinical trial for Healight in SARS-CoV-2 patients. The financial position was bolstered by a $15 million debt refinancing.
Aytu BioPharma (NASDAQ:AYTU) has refinanced its existing senior secured loan facility by entering into a $15 million agreement with Avenue Capital Group.
This refinancing includes an interest rate based on prime plus 7.4% and a flexible repayment structure, allowing up to 36 months of interest-only payments contingent on certain milestones.
The funds will support Aytu's ongoing clinical studies, including a registrational study of AR101 for vascular Ehlers-Danlos Syndrome and a study of Healight for SARS-CoV-2.
Aytu BioPharma (NASDAQ:AYTU) has appointed Mark Oki as its new Chief Financial Officer, effective January 17, 2022. Oki joins the executive committee, reporting to CEO Josh Disbrow. His role will focus on financial operations, accounting, and IT. Oki brings over 20 years of experience in finance within the biotech and pharmaceutical industries, previously serving as CFO of Vivus LLC. Upon starting, he will receive an inducement grant of 100,000 shares, vesting over three years. This appointment aims to enhance growth strategies and leverage financial expertise for Aytu's pipeline advancements.
Aytu BioPharma (NASDAQ:AYTU) announced that CEO Josh Disbrow will present a pre-recorded presentation at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 a.m. ET. The presentation will be available for on-demand viewing on the company's website for 90 days. Aytu is known for its innovative prescription products for ADHD and pediatric conditions, including Adzenys XR-ODT and Cotempla XR-ODT. The company also focuses on treatments for insomnia and has a developing pipeline for rare diseases like vascular Ehlers-Danlos Syndrome.
Denovo Biopharma announced that its partner Aytu BioPharma (Nasdaq: AYTU) has received FDA clearance for its IND application for enzastaurin and Orphan Drug Designation (ODD) for treating Vascular Ehlers-Danlos Syndrome (VEDS). The IND clearance allows Aytu to initiate the PREVEnt Trial in VEDS in 2022, evaluating enzastaurin's safety and efficacy. ODD status provides financial incentives and potential market exclusivity for the drug. VEDS is a severe condition affecting 1 in 50,000 people worldwide, with no FDA-approved therapies available.
Aytu BioPharma (NASDAQ:AYTU) announced FDA clearance of the IND application for AR101 (enzastaurin), allowing the initiation of the pivotal PREVEnt Trial for treating vascular Ehlers-Danlos Syndrome (VEDS). The trial aims to assess the safety and efficacy of enzastaurin in patients with confirmed COL3A1 mutations. Currently, there are no FDA-approved therapies for VEDS, affecting 1 in 50,000 individuals. The trial, set to begin in the first half of 2022, expects to enroll about 260 patients and will focus on reducing fatal and non-fatal arterial events.